Blood marker may predict prostate cancer drug response
NCT ID NCT02125617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a new drug combo tame resistant prostate cancer?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- Can a new daily pill slow advanced prostate cancer?